Anthony R. Mato, MD, MSCE

Articles

Optimizing the Treatment of CLL With Novel Therapies

March 14th 2022

Oncologist-hematologists discuss the outlook for treating patients with chronic lymphocytic leukemia with newer novel therapies.

CAR T-Cell Therapies in CLL

March 14th 2022

Take-home messages from ASH 2021 regarding the role of CAR T-cell therapies in chronic lymphocytic leukemia.

PI3K Inhibitors for CLL

March 7th 2022

A comparison of 3 PI3K inhibitors—idelalisib, duvelisib, and umbralisib—as treatment for chronic lymphocytic leukemia.

Novel Therapies for CLL: Sequencing Strategies

February 28th 2022

Factors that impact decisions for frontline and subsequent lines of therapy for patients with chronic lymphocytic leukemia.

Chemotherapy-Free Regimens as Frontline Therapy in CLL

February 21st 2022

Key takeaways of the CLL13 (GAIA) clinical trial based on highlights presented at ASH 2021.

Fixed-Duration Therapy in Relapsed/Refractory CLL: Ibrutinib Plus Venetoclax

February 14th 2022

Considerations for treating patients with relapsed/refractory chronic lymphocytic leukemia with the combination of ibrutinib and venetoclax.

Fixed-Duration Therapy in Frontline CLL: Venetoclax Plus Obinutuzumab

February 14th 2022

The rationale for investigating the fixed-duration, all-oral combination regimen of venetoclax with obinutuzumab as treatment for chronic lymphocytic leukemia.

Fixed-Duration Therapy in Frontline CLL: Ibrutinib Plus Venetoclax

February 7th 2022

Key takeaways from the CAPTIVATE and GLOW trials of ibrutinib plus venetoclax as fixed-duration frontline therapy for chronic lymphocytic leukemia.

Frontline Therapy for CLL: Treatment Selection Based on Patient and Treatment Factors

February 7th 2022

Variables that impact which Bruton tyrosine kinase inhibitor is most appropriate as frontline therapy for patients with newly diagnosed chronic lymphocytic leukemia and the role of patient and disease factors in treatment selection.

Chronic Lymphocytic Leukemia: Novel Therapies in the Pipeline

January 31st 2022

Exciting novel-based treatment strategies being investigated in chronic lymphocytic leukemia.

Novel Combination Regimens for Chronic Lymphocytic Leukemia

January 31st 2022

Implications for treating chronic lymphocytic leukemia with small molecule combination regimens in the frontline setting.

PI3K Inhibitors for Chronic Lymphocytic Leukemia

January 31st 2022

The rationale for investigating and using PI3K inhibitors to treat chronic lymphocytic leukemia.

Individualizing Therapy for Patients With Newly Diagnosed CLL

January 24th 2022

Susan O’Brien, MD, and Anthony Mato, MD, MSCE, describe their preferences for treating newly diagnosed chronic lymphocytic leukemia based on disease presentation and patient variables.

Frontline Anti-CD20 Therapy in CLL

January 24th 2022

The rationale for integrating CD20 monoclonal antibody therapy into the frontline setting of chronic lymphocytic leukemia.

BTK Inhibitors as Frontline Therapy for CLL

January 24th 2022

The rationale for using Bruton tyrosine kinase inhibitors, such as the first-generation option, ibrutinib, as first-line treatment for chronic lymphocytic leukemia.

Frontline Targeted Therapy for Newly Diagnosed High-Risk CLL

January 17th 2022

Frontline therapies available to treat newly diagnosed high-risk chronic lymphocytic leukemia, and the rationale for selecting a targeted therapy versus chemoimmunotherapy as initial treatment.

Impressions Regarding an Atypical Case of High-Risk CLL

January 17th 2022

Reactions to an atypical diagnosis of high-risk chronic lymphocytic leukemia in a 61-year-old man.

Optimizing Testing Rates in CLL: Q&A

November 24th 2021

Drs Alexey Danilov and Anthony Mato respond to a variety of questions pertaining to the assessment and treatment of patients with chronic lymphocytic leukemia.

Frontline Treatment Approaches in CLL

November 15th 2021

Drs Alexey Danilov and Anthony Mato review treatment options available for newly diagnosed chronic lymphocytic leukemia and describe decisions for monotherapy vs combination therapy.

Repeat Prognostic Testing in CLL

November 11th 2021

Drs Alexey Danilov and Anthony Mato recommend when hematologists and oncologists should consider repeat molecular testing for patients with chronic lymphocytic leukemia.